FDA Approves Yeztugo (lenacapavir) as the First and Only HIV . . . Yeztugo (lenacapavir) injection, 463 5 mg 1 5 mL, is indicated for pre‑exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents (>35kg) who are at risk for HIV-1 acquisition
FDA approval of injectable lenacapavir marks progress for HIV . . . WHO welcomes the approval by the United States Food and Drug Administration (FDA) of injectable lenacapavir for HIV prevention Administered just twice a year, lenacapavir offers sustained protection and adds to the growing range of HIV prevention options
FDA approves lenacapavir as a twice-a-year shot to prevent . . . The Food and Drug Administration has approved the world’s only twice-a-year shot to prevent HIV In two groundbreaking studies, Gilead Sciences’ shot, a drug named lenacapavir, nearly eliminated new infections in two groundbreaking studies of people at high risk